Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Denali Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4DN vs RCUS, ALMS, ELVN: FCF Margin % Comparison
For the Biotechnology subindustry, Denali Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (STU:4DN) has a FCF Margin % of -3,513.27% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Denali Therapeutics and its competitors. According to the industry distribution chart, Denali Therapeutics ranks #906 out of 957 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Denali Therapeutics' FCF Margin % too high?
Denali Therapeutics' current FCF Margin % is -3,513.27%. Based on the distribution chart, Denali Therapeutics ranks #906 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' FCF Margin % compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #906 out of 957 companies for FCF Margin %. This places Denali Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current FCF Margin % is -3,513.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €21.91 — trading 8326.9% above its estimated fair value. The current FCF Margin % is -3,513.27%. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current FCF Margin % is -3,513.27% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Denali Therapeutics (STU:4DN) Overvalued in 2026?
Based on GuruFocus' analysis, Denali Therapeutics stock appears to be overvalued.
The current stock price of €21.91 is trading 8326.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Denali Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:4DN:
FCF Margin %: -3,513.27%
GF Value™: €0.26 vs. price of €21.91 (8326.9% above fair value)
No single metric tells the full story. See the STU:4DN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score
Get the complete analysis for STU:4DN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4DN has been successfully added to your 
